PL3527210T3 - Kombinacja skojarzona zawierająca związek benzoheterocykliczny i modulator szlaku receptora androgenowego oraz jej zastosowania - Google Patents

Kombinacja skojarzona zawierająca związek benzoheterocykliczny i modulator szlaku receptora androgenowego oraz jej zastosowania

Info

Publication number
PL3527210T3
PL3527210T3 PL17881171T PL17881171T PL3527210T3 PL 3527210 T3 PL3527210 T3 PL 3527210T3 PL 17881171 T PL17881171 T PL 17881171T PL 17881171 T PL17881171 T PL 17881171T PL 3527210 T3 PL3527210 T3 PL 3527210T3
Authority
PL
Poland
Prior art keywords
androgen receptor
receptor pathway
combined composition
pathway modulator
benzoheterocyclic compound
Prior art date
Application number
PL17881171T
Other languages
English (en)
Inventor
Chuansheng Ge
Baisong Liao
Wen-Cherng Lee
Original Assignee
Kangpu Biopharmaceuticals, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kangpu Biopharmaceuticals, Ltd. filed Critical Kangpu Biopharmaceuticals, Ltd.
Publication of PL3527210T3 publication Critical patent/PL3527210T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL17881171T 2016-12-16 2017-12-15 Kombinacja skojarzona zawierająca związek benzoheterocykliczny i modulator szlaku receptora androgenowego oraz jej zastosowania PL3527210T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201611170723 2016-12-16
EP17881171.7A EP3527210B1 (en) 2016-12-16 2017-12-15 Combined composition comprising a benzoheterocyclic compound and an androgen receptor pathway modulator and uses thereof
PCT/CN2017/116413 WO2018108147A1 (zh) 2016-12-16 2017-12-15 一种组合、其应用及治疗方法

Publications (1)

Publication Number Publication Date
PL3527210T3 true PL3527210T3 (pl) 2021-11-29

Family

ID=62558044

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17881171T PL3527210T3 (pl) 2016-12-16 2017-12-15 Kombinacja skojarzona zawierająca związek benzoheterocykliczny i modulator szlaku receptora androgenowego oraz jej zastosowania

Country Status (15)

Country Link
US (1) US10933059B2 (pl)
EP (1) EP3527210B1 (pl)
JP (1) JP7048106B2 (pl)
KR (2) KR20220028178A (pl)
CN (1) CN110049765B (pl)
AU (1) AU2017376704B2 (pl)
BR (1) BR112019010559B1 (pl)
CA (1) CA3046869C (pl)
DK (1) DK3527210T3 (pl)
ES (1) ES2884064T3 (pl)
PL (1) PL3527210T3 (pl)
PT (1) PT3527210T (pl)
RU (1) RU2731535C1 (pl)
WO (1) WO2018108147A1 (pl)
ZA (1) ZA201904328B (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA55628A (fr) 2019-04-12 2022-02-16 C4 Therapeutics Inc Agents de dégradation tricycliques d'ikaros et d'aiolos
WO2025195464A1 (zh) * 2024-03-21 2025-09-25 上海惠康济民生物医药技术有限公司 取代的异吲哚啉类化合物、制备方法、药物组合物及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100534498B1 (ko) 1996-07-24 2005-12-08 셀진 코포레이션 치환된 2-(2,6-디옥소피페리딘-3-일)-프탈이미드와 치환된 2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린과 TNFα농도를 감소시키는 방법
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
CN110003114B (zh) 2005-05-13 2023-01-17 加利福尼亚大学董事会 二芳基乙内酰脲化合物
ME02890B (me) 2006-09-26 2018-04-20 Celgene Corp Derivati 5-supstituisanog hinazolinona kao antikancer agensi
CN101679380A (zh) * 2007-03-20 2010-03-24 细胞基因公司 4’-o-取代的异吲哚啉衍生物和包含它的组合物及使用方法
US9045453B2 (en) 2008-11-14 2015-06-02 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
KR101649332B1 (ko) 2008-11-14 2016-08-18 콘서트 파마슈티컬즈, 인크. 치환된 다이옥소피페리디닐 프탈이미드 유도체
HUE042011T2 (hu) 2010-02-11 2019-06-28 Celgene Corp Arilmetoxi-izoindolin-származékok, azok készítményei és alkalmazási módszereik
WO2012079022A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
SG11201401471PA (en) 2011-11-30 2014-08-28 Astrazeneca Ab Combination treatment of cancer
SMT201900735T1 (it) * 2012-07-27 2020-03-13 Aragon Pharmaceuticals Inc Metodi e composizioni per determinare la resistenza a una terapia verso recettore degli androgeni
ES2814952T3 (es) 2012-09-04 2021-03-29 Celgene Corp Isotopólogos de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il) piperidina-2-6-diona y métodos de preparación de los mismos
EP2943201B2 (en) 2013-01-14 2020-07-29 Deuterx, LLC 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
LT2945628T (lt) * 2013-01-15 2020-05-25 Aragon Pharmaceuticals, Inc. Androgeno receptoriaus moduliatorius derinyje su abiraterono acetatu ir prednizonu, skirtas prostatos vėžio gydymui
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
AP2015008838A0 (en) 2013-05-10 2015-11-30 Univ British Columbia Industry Liaison Office Ester derivatives of androgen receptor modulators and methods for their use
CN105566290B (zh) * 2014-10-30 2020-05-22 康朴生物医药技术(上海)有限公司 异吲哚啉衍生物、其中间体、制备方法、药物组合物及应用
JP6633744B2 (ja) * 2015-09-29 2020-01-22 カング バイオファーマシューティカルズ リミテッド 医薬組成物及びその応用
KR102125661B1 (ko) * 2017-02-13 2020-06-22 강푸 바이오파마슈티칼즈 리미티드 전립선암 치료용 조합, 약학 조성물 및 치료 방법

Also Published As

Publication number Publication date
JP2020510620A (ja) 2020-04-09
NZ753549A (en) 2021-10-29
JP7048106B2 (ja) 2022-04-05
DK3527210T3 (da) 2021-08-09
ZA201904328B (en) 2020-12-23
KR102368555B1 (ko) 2022-02-28
CA3046869A1 (en) 2018-06-21
ES2884064T3 (es) 2021-12-10
CN110049765A (zh) 2019-07-23
CN110049765B (zh) 2022-02-01
RU2731535C1 (ru) 2020-09-04
KR20190097007A (ko) 2019-08-20
EP3527210A1 (en) 2019-08-21
PT3527210T (pt) 2021-08-11
BR112019010559B1 (pt) 2024-01-30
US10933059B2 (en) 2021-03-02
BR112019010559A2 (pt) 2019-12-03
CA3046869C (en) 2022-05-17
EP3527210B1 (en) 2021-06-09
AU2017376704B2 (en) 2021-08-05
US20190328722A1 (en) 2019-10-31
KR20220028178A (ko) 2022-03-08
WO2018108147A1 (zh) 2018-06-21
AU2017376704A1 (en) 2019-06-13
EP3527210A4 (en) 2019-11-20

Similar Documents

Publication Publication Date Title
IL281240B (en) Androgen receptor modulator and uses thereof
IL285318A (en) Estrogen receptor modulators
SG11201606876RA (en) Toll like receptor modulator compounds
PL3625300T3 (pl) Materiały spoiwa
GB201717974D0 (en) Modified receptors
IL249267A0 (en) Materials containing carbonitrile and their use for selective modulation of the androgen receptor
IL268263B (en) Estrogen receptor modulators
SG11201710234SA (en) Slide ring seal arrangement comprising release protection
SG11202003569QA (en) Insect release devices
HUE061436T2 (hu) Új analógok mint androgén receptor és glükokortikoid receptor modulátorok
KR102176229B9 (ko) 밀봉재 조성물
GB201719837D0 (en) Seal protection mechanism
IL270273B1 (en) Highly charged drug formulations with enhanced sustained release
GB201601838D0 (en) A composition
PL3527210T3 (pl) Kombinacja skojarzona zawierająca związek benzoheterocykliczny i modulator szlaku receptora androgenowego oraz jej zastosowania
PL3568203T3 (pl) Związki i kompozycje
PL3380558T3 (pl) Półprzewodząca kompozycja polietylenu
PL3380559T5 (pl) Półprzewodząca kompozycja polietylenu
EP3135669A4 (en) Oxazolidine-based compound and selective androgen receptor agonist comprising same
GB201616071D0 (en) Receptor modulator compounds
GB201616065D0 (en) Receptor modulator compounds
GB201616072D0 (en) Receptor modulator compounds
GB201711319D0 (en) Autotrip anchor release
GB201710931D0 (en) Package
GB201512714D0 (en) Receptor modulator compounds